New FDA and DSCSA Compliance Requirements U.S. Drug Distributors Must Follow in 2026

The pharmaceutical industry in the United States continues to adapt to significant regulatory changes under the Drug Supply Chain Security Act (DSCSA). As we move through 2026, drug distributors, pharmacies, and other stakeholders face critical compliance deadlines that will reshape how medications move through the supply chain.

Understanding these requirements is essential for any wholesale pharmacy operating in the industry today. The FDA has made it clear that enforcement is no longer theoretical—it's happening now.

What is the DSCSA?

The DSCSA provides for the tracking and tracing of drug products from drug manufacturers through the supply chain down to dispensers. This includes rules for investigating and handling suspicious or counterfeit medications, along with federal licensing standards for wholesalers and third-party logistics companies. The law aims to prevent counterfeit drugs from entering the supply chain and protect patients from potentially dangerous medications.

The act requires manufacturers, repackagers, wholesale distributors, third-party logistics providers, and dispensers to follow specific rules when transferring ownership of prescription drugs.

Timeline of Critical Deadlines

The FDA adopted a phased approach for compliance after recognizing that the industry needed more time to implement electronic data exchange systems. Here's where we stand:

Already Enforced (2025):

• Manufacturers and Repackagers: Deadline passed May 27, 2025
• Wholesale Distributors: Deadline passed August 27, 2025

Active Enforcement Period (2025-2026):

• Large Dispensers (26+ pharmacists/technicians): Deadline November 27, 2025
• Small Dispensers (25 or fewer staff): Deadline November 27, 2026

FDA is issuing exemptions from certain requirements of section 582 of the FD&C Act to small dispensers (pharmacies), and where applicable, their trading partners, until November 27, 2026. This gives smaller pharmacies additional time to stabilize their operations and implement the necessary technology systems.

Key Requirements for Drug Distributors in 2026

Electronic Transaction Data:

All trading partners must now exchange transaction information and transaction statements in a secure, electronic, and interoperable manner. Manufacturers, distributors and dispensers must provide and receive transaction information (including product identifier) and transaction statements in a secure, electronic, and interoperable manner.

This means paper-based systems are no longer acceptable. Every prescription drug package must be tracked electronically throughout its journey from manufacturer to patient.

Product Identifiers:

Each drug package must have a unique identifier that includes:

• National Drug Code (NDC)
• Serial number
• Lot number
• Expiration date

These identifiers use GS1 standards, with products identified by Global Trade Identification Numbers (GTIN) and trading partners identified by Global Location Numbers (GLN).

Verification Systems:

Distributors must have systems in place to verify product identifiers at the package level. This is particularly important for saleable returns. Distributors must now confirm product authenticity, send transaction data through electronic systems, and handle discrepancies as they occur.

When a pharmacy returns medication to a wholesale pharmacy in the USA, the distributor must verify that the product identifier matches the original transaction data before accepting it back into inventory for resale.

Authorized Trading Partners:

All entities in the supply chain must be authorized trading partners. This means:

• Manufacturers must have valid FDA registration
• Wholesale distributors must maintain state or federal licenses
• Dispensers must hold valid state pharmacy licenses
• All parties must verify their partners' credentials before conducting transactions

What Small Dispensers Need to Know

A dispenser is considered a small dispenser, for these exemptions, if, as of November 27, 2024, the company that owns the dispenser has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians.

If your pharmacy qualifies as a small dispenser, you have until November 27, 2026 to fully comply with the enhanced requirements. However, the FDA urges small dispensers to continue implementation efforts rather than delay until the deadline.

Small dispensers don't need to notify the FDA that they're using this exemption—pharmacies must determine their own eligibility based on staffing numbers.

Consequences of Non-Compliance

The FDA has made enforcement a priority. Violations can result in:

• Product seizures
• Court-ordered injunctions
• Civil and criminal penalties, including fines
• Potential imprisonment for serious violations
• Product quarantine and destruction
• Return rejections from distributors
• Cash flow disruption

In prior warning letters, the agency has highlighted failure to maintain effective verification processes as a violation with potential enforcement consequences. The FDA has already issued warning letters and criminal indictments for DSCSA violations, signaling that enforcement is real and ongoing.

Managing Real-Time Exceptions

One of the biggest challenges facing distributors is handling exceptions—situations where transaction data doesn't match, serial numbers are missing, or verification systems experience downtime.

A shipment on hold because it cannot be verified is not just a compliance issue—it can delay life-saving medicines, cause product to be rejected or destroyed, and generate costly returns and dispute fees.

Distributors need dedicated resources and processes to:

• Investigate data mismatches quickly
• Correct transaction information errors
• Communicate with trading partners about discrepancies
• Quarantine product until verification is complete

Drugzone's Approach to DSCSA Compliance

As the pharmaceutical industry faces these regulatory changes, distributors like Drugzone Pharmaceuticals Inc. have positioned themselves to help healthcare providers navigate compliance requirements. Operating as a NABP-accredited and FDA-registered distributor, Drugzone maintains DSCSA 2025 compliance standards while serving customers across all 50 states.

Drugzone's compliance infrastructure includes electronic data exchange capabilities, verification systems for product identifiers, and proper handling of transaction information for both general and specialty medications. The company works with hospitals, veterinary clinics, long-term care facilities, and independent pharmacies to provide medications while meeting federal tracking and tracing requirements.

For pharmacies working to meet November 2026 deadlines, partnering with compliant distributors helps reduce regulatory burden. Distributors who have already implemented electronic serialization systems can provide the necessary transaction data and support that pharmacies need to stay compliant.

Frequently Asked Questions

Q: What happens if a distributor can't verify a returned product?

A: If verification fails, the distributor cannot accept the product back into saleable inventory. The product must be quarantined and potentially destroyed, resulting in financial loss for the pharmacy attempting the return. This is why maintaining accurate transaction records is critical.

Q: Are all prescription drugs covered under DSCSA requirements?

A: No. The DSCSA applies to prescription drugs in finished dosage form for human use. Exemptions include blood products, radioactive drugs, imaging drugs, certain IV products, medical gases, homeopathic drugs, and lawfully compounded medications.

Q: Do small dispensers need to report their exemption status to the FDA?

A: No. Small dispensers and their trading partners who utilize the exemptions do not need to submit anything to the FDA or inform the agency. Pharmacies must make their own determination of whether they meet the small dispenser definition based on staffing levels.

Article Author

Binu .B RPH

President

With more than 20 years of experience in the pharmaceutical wholesale sector, I have Founded and managed several companies, including a pharmaceutical wholesale company, a compounding/retail pharmacy,and many more. As the president of Drugzone Pharmaceuticals Inc., I develop new business and maintain existing business relationships.